Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical guidelines and treatment modalities without systematic review methodology
PubMed 38505500 · doi:10.2147/JPR.S442595
What was done
This narrative review summarizes current US clinical guidelines and treatment options for painful diabetic peripheral neuropathy (DPN). The authors specifically examined evidence for US Food and Drug Administration (FDA)-approved therapies (including oral medications, topical agents, and spinal cord stimulation devices), off-label first-line options, and emerging therapeutic approaches.
What was found
The abstract provides no quantitative data or effect sizes. It reports that four pharmacologic agents are FDA-approved for painful DPN (oral duloxetine, pregabalin, and tapentadol extended release, plus the capsaicin 8% topical system) alongside several recently approved spinal cord stimulation (SCS) devices for refractory pain. Common first-line oral classes used in practice without specific DPN FDA approvals include tricyclic antidepressants, serotonin/norepinephrine reuptake inhibitors, gabapentinoids, and sodium channel blockers.
Why it matters
This review provides a consolidated overview of current US guideline recommendations and FDA-approved modalities—especially newer additions like high-concentration topical capsaicin and spinal cord stimulation—to help clinicians navigate multimodal pain management for diabetic neuropathy.
Limits
The abstract describes a non-systematic narrative review without reported search methods, inclusion criteria, or pooled quantitative data. It does not provide primary clinical outcome metrics, comparative effectiveness statistics, adverse event rates, or the number of evaluated studies.
Cited by
- supports Pregabalin was approved by the FDA for the treatment of diabetic neuropathy pain.